The U.S. Food and Drug Administration (FDA) recently approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALZENNA is the first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with this condition. The FDA’s approval of the combination treatment is based on the findings from the pivotal TALAPRO-2 study, which demonstrated a 55% reduction in the risk of progression or death among HRR gene-mutated tumors in patients with metastatic castration-resistant prostate cancer. This was a trial that PHEN supported through its Clinical Trials Rally. Patients participating in this trial were the first to benefit from its success, while also helping to establish a new treatment protocol that will help other patients along their prostate cancer journeys.
“PHEN is really excited to have supported the trial that led to this treatment breakthrough,” says Dr. Keith Crawford, PHEN’s Director of Clinical Trials and Patient Education.
